'The pension gap has grown only by two per cent since 1976,' writes HOOPP's head of plan services
As plan sponsors consider the costs and efficacy of GLP-1 drugs, they should not ignore alternatives
A multi-manager, multi-strategy approach to private markets investing can optimize for returns, volatility and liquidity
How an employer's perspective on and handling of fertility and family-planning benefits can help or hinder workplace culture
